When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

Published Date: 15 Dec 2023

Improvements in 2-year PFS and OS, but not for primary refractory illness.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

2.

Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery

3.

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

4.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

5.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot